Do p38 mitogen-activated protein kinase inhibitors have a future for the treatment of cardiovascular disease?

Acute coronary syndrome (ACS) is associated with a significant risk of cardiovascular death, and recurrent ischemic events including myocardial infarction (MI). Therapeutic interventions for the management of ACS utilize a thrombolytic approach, although this is associated with an increased risk of bleeding.